Progress in AIDS vaccine development

Because of a unique combination of challenges facing human immunodeficiency virus vaccine developers, a number of traditional and novel vaccine designs are being evaluated essentially in parallel. Monomeric proteins, poxvirus vectors, peptides, and particle-based candidate vaccines have entered or w...

Full description

Saved in:
Bibliographic Details
Published inInternational archives of allergy and immunology Vol. 108; no. 4; p. 313
Main Author Johnston, M I
Format Journal Article
LanguageEnglish
Published Switzerland 01.12.1995
Subjects
Acquired Immunodeficiency Syndrome - prevention & control
Acquired Immunodeficiency Syndrome - transmission
AIDS Vaccines - immunology
Animals
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Drug Design
Gene Products, env - immunology
Gene Products, gag - immunology
HIV Antigens - immunology
HIV Infections - prevention & control
HIV Infections - transmission
Humans
Poxviridae - genetics
Vaccines, Synthetic - immunology
Online AccessGet more information

Cover

More Information
Summary:Because of a unique combination of challenges facing human immunodeficiency virus vaccine developers, a number of traditional and novel vaccine designs are being evaluated essentially in parallel. Monomeric proteins, poxvirus vectors, peptides, and particle-based candidate vaccines have entered or will soon enter human trials. Other designs are at earlier stages of development. All candidates evaluated to date in phase I/II human trials have proven safe and immunogenic. One or more of the most promising designs will soon progress to 'test of concept' clinical trials to determine efficacy.
ISSN:1018-2438
DOI:10.1159/000237173